Home > In process > Distinct cerebrospinal fluid profiles of astrocytic aquaporin-4 and GFAP in neuroinflammatory disorders. > print

001     286093
005     20260413130803.0
024 7 _ |a 10.1016/j.nbd.2026.107351
|2 doi
024 7 _ |a pmid:41831579
|2 pmid
024 7 _ |a 0969-9961
|2 ISSN
024 7 _ |a 1095-953X
|2 ISSN
037 _ _ |a DZNE-2026-00389
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Halbgebauer, Steffen
|0 P:(DE-2719)9002026
|b 0
|u dzne
245 _ _ |a Distinct cerebrospinal fluid profiles of astrocytic aquaporin-4 and GFAP in neuroinflammatory disorders.
260 _ _ |a [Amsterdam]
|c 2026
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1776078365_32198
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Aquaporin 4 (AQP4), a water channel expressed in astrocytic end feet forming the blood brain barrier, is predominantly expressed in the central nervous system. Cerebrospinal fluid (CSF) AQP4 has now been suggested as a possible fluid biomarker in Alzheimer's disease. However, its diagnostic potential in primary neuroinflammatory diseases, where also AQP4 autoantibodies can circulate, has so far not been studied. We investigated the CSF of 301 patients for AQP4 and GFAP using ELISA. The single-center cohort consisted of patients with multiple sclerosis (n = 81), chronic inflammatory demyelinating polyneuropathy (n = 23), Guillain-Barré-Syndrome (n = 13), meningitis/ encephalitis (Men/Enc) (n = 19), myelin oligodendrocyte glycoprotein antibody disease (n = 6), neuromyelitis optica spectrum disease (NMOSD) (n = 12), and non-immune mediated polyneuropathy (NIP) patients (n = 49). 98 patients without acute or chronic neuroinflammation and neurodegneration served as controls. Both CSF AQP4 (r = 0.45 (95%CI: 0.36-0.54), p < 0.0001) and GFAP (r = 0.4 (95%CI: 0.30-0.49), p < 0.0001) correlated with age in the whole cohort. CSF AQP4 levels were elevated in the NIP group compared to control, MS and Men/Enc patients (p = 0.002, p = 0.029 and 0.005, respectively). When stratified further, the hereditary NIP patients (n = 26) displayed the highest AQP4 levels of all groups. CSF GFAP was elevated in the AQP4 autoantibody positive NMOSD group but was not increased in AQP4 autoantibody negative NMOSD patients. CSF AQP4 levels were similar in both NMOSD groups. Combining AQP4 and GFAP levels or calculating their ratio did not prominently enhance diagnostic discrimination. The study highlights the diagnostic potential of AQP4 as a fluid biomarker in neurological conditions, especially in peripheral neuropathies, while confirming GFAP as marker for astrocytic injury in autoantibody positive NMOSD patients. Our findings suggest that AQP4 and GFAP reflect different astrocytic processes in neurological diseases.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Aquaporin 4
|2 Other
650 _ 7 |a Astrocytes
|2 Other
650 _ 7 |a Biomarker
|2 Other
650 _ 7 |a Cerebrospinal fluid
|2 Other
650 _ 7 |a GFAP
|2 Other
650 _ 7 |a Aquaporin 4
|2 NLM Chemicals
650 _ 7 |a AQP4 protein, human
|2 NLM Chemicals
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Glial Fibrillary Acidic Protein
|2 NLM Chemicals
650 _ 7 |a GFAP protein, human
|2 NLM Chemicals
650 _ 7 |a Autoantibodies
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Aquaporin 4: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Biomarkers: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Astrocytes: metabolism
|2 MeSH
650 _ 2 |a Glial Fibrillary Acidic Protein: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Neuroinflammatory Diseases: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Neuroinflammatory Diseases: diagnosis
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
650 _ 2 |a Young Adult
|2 MeSH
650 _ 2 |a Autoantibodies: cerebrospinal fluid
|2 MeSH
700 1 _ |a Winger, Niklas
|b 1
700 1 _ |a Elmas, Zeynep
|b 2
700 1 _ |a Fazeli, Badrieh
|b 3
700 1 _ |a Bachhuber, Franziska
|b 4
700 1 _ |a Erhart, Deborah K
|b 5
700 1 _ |a Soylu, Önder
|b 6
700 1 _ |a Klassen, Paula
|0 P:(DE-2719)9001969
|b 7
|u dzne
700 1 _ |a Senel, Makbule
|b 8
700 1 _ |a Dorst, Johannes
|0 P:(DE-2719)9001951
|b 9
|u dzne
700 1 _ |a Haeusler, Karl Georg
|b 10
700 1 _ |a Weishaupt, Jochen H
|0 P:(DE-2719)9000455
|b 11
700 1 _ |a Otto, Markus
|b 12
700 1 _ |a Tumani, Hayrettin
|0 P:(DE-2719)9002007
|b 13
|u dzne
773 _ _ |a 10.1016/j.nbd.2026.107351
|g Vol. 222, p. 107351 -
|0 PERI:(DE-600)1471408-5
|p 107351
|t Neurobiology of disease
|v 222
|y 2026
|x 0969-9961
856 4 _ |u https://pub.dzne.de/record/286093/files/DZNE-2026-00389.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/286093/files/DZNE-2026-00389.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 0
|6 P:(DE-2719)9002026
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)9001969
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 9
|6 P:(DE-2719)9001951
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)9000455
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 13
|6 P:(DE-2719)9002007
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2025-08-21T14:53:16Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2025-08-21T14:53:16Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2025-08-21T14:53:16Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-11-11
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROBIOL DIS : 2022
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-11-11
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-11-11
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NEUROBIOL DIS : 2022
|d 2025-11-11
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-11-11
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-11-11
920 1 _ |0 I:(DE-2719)5000077
|k Clinical Study Center (Ulm)
|l Clinical Study Center (Ulm)
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)5000077
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21